1. Home
  2. ESLT vs GMAB Comparison

ESLT vs GMAB Comparison

Compare ESLT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elbit Systems Ltd.

ESLT

Elbit Systems Ltd.

HOLD

Current Price

$699.39

Market Cap

21.8B

Sector

Industrials

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$33.82

Market Cap

21.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESLT
GMAB
Founded
1966
1999
Country
Israel
Denmark
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.8B
21.1B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
ESLT
GMAB
Price
$699.39
$33.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$550.33
$40.40
AVG Volume (30 Days)
133.7K
1.5M
Earning Date
11-18-2025
02-11-2026
Dividend Yield
0.38%
N/A
EPS Growth
68.63
132.41
EPS
9.87
25.10
Revenue
$7,720,284,000.00
$3,845,670,022.00
Revenue This Year
$18.47
$24.85
Revenue Next Year
$10.93
$16.51
P/E Ratio
$72.68
$1.35
Revenue Growth
18.35
29.57
52 Week Low
$286.04
$17.24
52 Week High
$719.99
$34.30

Technical Indicators

Market Signals
Indicator
ESLT
GMAB
Relative Strength Index (RSI) 82.12 59.63
Support Level $574.29 $30.35
Resistance Level $719.99 $34.30
Average True Range (ATR) 14.38 0.68
MACD 10.90 0.12
Stochastic Oscillator 87.08 87.83

Price Performance

Historical Comparison
ESLT
GMAB

About ESLT Elbit Systems Ltd.

Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: